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12 Oral Presentationsstudies also reinforce a critical role for donor APCs in the pathogen-
esis of GVHD.
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BENZODIAZEPINE-423, AN INHIBITOR OF MITOCHONDRIAL RESPIRA-
TION, CAUSES SELECTIVE APOPTOSIS OF ACTIVATED LYMPHOCYTES
AND REVERSES EXPERIMENTAL GVHD WHILE PRESERVING GVL EF-
FECTS
Gatza, E., Clouthier, S.G., Rogers, C.E., Reddy, P., Opipari, A.W.,
Glick, G.D., Ferrara, J.L.M. University of Michigan, Ann Arbor, MI.
Benzodiazepine (Bz)-423 targets activated lymphocytes through
the mitochondrial F1F0-ATPase, causing loss of mitochondrial
membrane potential and apoptosis without affecting resting lym-
phocytes. We tested Bz-423 in a non-irradiated B6-Ly5.2/
B6F2F1 model of GVHD where donor cells were labeled with
CFSE to discriminate between activated (CFSElo) and unactivated
(CFSEhi) Ly5.21 donor or host Ly5.11 lymphocytes. Compared
to controls, Bz-423 caused loss of mitochondrial membrane polar-
ization within 6 h of delivery as measured by 3,30-dihexyloxacarbo-
cyanine iodide (DiOC6(3)) staining in both activated donor CD4
1
(32.6% vs 23.1%, p 5 0.04) and CD81 (34.5% vs 24.4%, p 5
0.04) T cells but not in unactivated donor or host cells. Loss of mi-
tochondrial membrane potential was followed by selective apoptosis
of donor CD41 (39.1% vs 25.5%, p 5 0.02) and CD81 (41.4% vs
25.9%, p 5 0.002) T cells. Injection of 60 mg/kg Bz-423 3 times
weekly beginning 7 d after GVHD induction significantly reduced
mortality (50% vs 100%, p \ 0.02). We next used Bz-423 in
a miHA-disparate, CD81 T cell-mediated model of GVHD
(C3H.SW/B6) in which B6 hosts received 9Gy of TBI and injec-
tion of 5  106 C3H.SW BM and 4  106 T cells, again initiating
Bz-423 injections 7 d after BMT. The drug significantly reduced
GVHD clinical scores and improved survival compared to controls
(74% vs 29%, p # 0.02). Bz-423 also reduced GVHD histologic
damage indices in the liver (3.6 vs 11.2, p\ 0.03) and the GI tract
(7.0 vs 15.8, p\0.02). Bz-423 reduced IFN-g, a knownmediator of
GVHD, in the serum (8.4 vs 21.7 pg/ml, p\ 0.03) and decreased
IFN-g1CD81 effector spleen T cells (0.64  105 vs 2.2  105,
p 5 0.008), but did not impair the lysis of tumor targets by CD81
T cells ex vivo. We tested Bz-423 next in a GVL model where
EL-4 lymphoma cells syngeneic to B6 recipients were injected on
the day of BMT. No recipients of syngeneic BMT survived EL-4
challenge (0/12) and no untreated allogeneic BMT survived
GVHD (0/12) but 9/14 (64%) of Bz-423 treated allogeneic recipi-
ents were alive on day 50 without evidence of lymphoma (p 5
0.003). We confirmed the effectiveness of Bz-423 in a third model
of GVHD to MHC differences (Balb/c/B6) where again
GVHD was reduced, survival was improved (58% vs 8%, p \
0.002) and GVL effects preserved. We conclude that Bz-423,
a first-in-class compound that selectively inhibits mitochondrial
respiration and causes apoptosis of activated lymphocytes, can
reverse experimental GVHD while preserving beneficial GVL
effects.26
EPITHELIAL APOPTOSIS IN ORAL CHRONIC GVHD IS MEDIATED BY EF-
FECTOR-MEMORY CD8 CELLS: POTENTIAL ROLE OF IL-15
Imanguli, M.M.1, Swaim, W.D.2, League, S.C.1, Guadagnini, J.-P.3,
Pavletic, S.Z.1, Gress, R.E.1, Hakim, F.T.1. 1National Cancer Institute,
Bethesda, MD; 2National Institute for Dental and Craniofacial Research,
Bethesda, MD; 3National Institute for Dental and Craniofacial Research,
Bethesda, MD.
Although chronic Graft versus Host Disease (cGVHD) is a major
long-term complication of allogeneic hematopoietic stem cell
transplantation, little is known of its pathogenesis. As part of an on-
going NCI cGVHD natural history protocol (04-C-0281), patients
were evaluated clinically for oral cGVHD parameters and biopsies
were collected from buccal mucosa. To assess histologic correlates
of the clinical symptoms, we quantified epithelial injury and mono-
nuclear cell infiltration using multi-parameter immunofluorescent
staining for active caspase 3 and CD45 and confocal microscopyon paraffin embedded tissues. The numbers of cleaved caspase-31
apoptotic cells within the epithelial layer correlated with clinical se-
verity assessed using the oral cGVHD grading scale. We then char-
acterized the cell populations in severely affected tissues. The
predominant infiltrating T-cells were CD31CD81 cells expressing
TIA-1 and Granzyme B, markers of cytotoxic effectors. Both CD8
and CD4 T-cells expressed T-bet, a transcription factor character-
istic of Type I cytokine producing cells. Consistent with this find-
ing, IFN-gamma levels as measured by quantitative PCR in split
biopsies positively correlated with the apoptotic index within the af-
fected oral epithelium (r 5 0.68), with total infiltrating CD8 cells
(r 5 .46) and particularly with proliferating CD8 cells as assessed
by double CD8/Ki67 staining (r 5 0.70). Since the infiltrating
CD8 cells expressed the markers of effector-memory lymphocytes
(CD45RO), we examined the expression of IL-15, a key cytokine
in the generation, proliferation and maintenance of effector-mem-
ory CD8 cells. We observed elevated IL-15 expression in both
the keratinocytes and infiltrating cells in the dermis of affected
oral mucosa. Mean fluorescent intensity of IL-15 in the epithelium
correlated with levels of granzyme BmRNA (r5 .72) in affected tis-
sues, consistent with IL-15 involvement in CD8 effector function.
We further investigated the balance of effector and regulatory T-
cells by immunofluorescent staining for FoxP3. FoxP31 cells were
quantitatively increased in severe oral cGVHD, but the proportion
of FoxP31 Treg cells in the total CD3 population remained con-
stant. Our findings suggest that infiltration of epithelial layers by
CD8 T-cells expressing T-Bet and cytotoxic markers are directly
involved in disease pathogenesis and that these cells may be sup-
ported by elevated IL-15 produced in the cGVHD epithelia.27
IL-17 IS REQUIRED FOR CD4-MEDIATED GVHD
Kappel, L.W.1,2, Goldberg, G.L.1, Ivanov, I.I.3, Na, I.-K.1, King, C.1,
Suh, D.1, Smith, O.M.1, Ligh, C.1, Littman, D.R.3,4, van den
Brink, M.R.M.1,2. 1Memorial Sloan-Kettering Cancer Center, New
York, NY; 2Weill Cornell College of Medical Sciences, New York, NY;
3Skirball Institute of BiomolecularMedicine, New YorkUniversity School
of Medicine, New York, NY; 4Howard Hughes Medical Institute.
Recently a new subset of CD41 T cells has been characterized,
which has been identified as IL-17 producing CD41 T cells or
Th17 cells. Naive T cells exposed to TGF-b and IL-6 differentiate
into Th17 cells by activating RORgt and STAT3 transcription fac-
tors. Th17 cells produce high levels of proinflammatory cytokines,
including IL-17, IL-21 and IL-22. These cells have been implicated
in allograft rejection of solid organs and several autoimmune dis-
eases, including rheumatoid arthritis, multiple sclerosis, inflamma-
tory bowel disease, and colitis.
Except for one report demonstrating the presence of Th17 cells
in a murine chronic graft versus host disease (GVHD) model, no
data have been presented regarding their role in acute GVHD.
Moreover, no studies have addressed the functional role of Th17
cells in GVHD. We first performed DNA microarray analyses of
the small intestine from mice with GVHD and found increased ex-
pression of Th17 related genes, including IL-17A, IL-17 receptor,
IL-6 and TGF-b. Using flow cytometric analysis we detected
CD41 IL-17 producing cells of donor origin at early time points
(day 10–14) after transplant in the spleen, mesenteric lymph nodes
(MLN), axillary lymph nodes and lamina propria in mice with
GVHD, but not in non-transplanted mice or transplanted mice
without GVHD.We confirmed these findings in two MHC-dispa-
rate models, as well as ELISA of the supernatant of in vitro stimu-
lated T cells from the spleen or MLN from mice with GVHD.
Interestingly, we observed significant numbers of alloreactive
CD41 T cells, which produce both IFN-g and IL-17, suggesting
that alloreactive T cells in vivo can express both Th1 andTh17 phe-
notypes simultaneously.
To assess whether Th17 cells are required for the development of
acute GVHD, we performed experiments with donor T cells from
IL-17 deficient mice. In a series of reproducible experiments with
varying doses of selected CD41T cells fromWT and IL-17-/- do-
nors, we found significantly less GVHDmorbidity and mortality in
the recipients of IL-17-/- T cells. Finally, preliminary experiments
Oral Presentations 13with CD41T cells from RORgt-/- vsWT donors suggest a signif-
icant survival benefit for recipients of RORgt-/- T cells. In conclu-
sion, these data suggest that CD41 Th17 cells contribute to the
development of acute GVHD.
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IL13 12044 (ARG130GLN) ASSOCIATES WITH ACUTE AND CHRONIC
GRAFT-VERSUS-HOST DISEASE FOLLOWING HAEMATOPOIETIC STEM
CELL TRANSPLANTATION
Leitch, E.A.1, Harrold, J.L.1, Ironside, A.1, Norden, J.1, Jackson, G.H.1,
Holler, E.2, Rocha, V.3, Socie, G.3, Hromadnikova, I.4, Sedlacek, P.4,
Greinix, H.5, Wolff, D.6, Urbano-Ispizua, A.7, Dickinson, A.M.1. 1Uni-
versity of Newcastle, Newcastle upon Tyne, Tyne andWear, United King-
dom; 2University of Regensburg, Regensburg, Germany; 3Hopital
Saint-Louis, Paris, France; 4Charles University, Prague, Czech Republic;
5University Hospital of Vienna, Vienna, Austria; 6Universitat Rostock,
Rostock, Germany; 7Hospital Clinic, Barcelona, Spain.
IL-13 is a T-helper 2 (Th2) cytokine that suppresses the cytotoxic
action of macrophages and inhibits the production of pro-inflam-
matory cytokines. A single nucleotide polymorphism (SNP) exists
within exon 4 of the IL13 gene at position 12044 which results in
an amino acid substitution (Arg130Gln). The high producer variant
(A allele) of this SNP, has been associated with several inflammatory
conditions, most notably asthma, and more recently IL-13 mixed
lymphocyte supernatant levels have been associated with aGvHD
in HSCT. Consequently the role of IL13 12044 SNP in HSCT
was examined in this investigation.
Polymorphism studies were carried out in a cohort of 923 HSCT
recipient and donors from 7 transplant centres across Europe. Gen-
otyping was performed using PCR and RFLP analysis. Univariant
(chi-squared) and multivariant (binary logistic regression) analyses
were performed to study associations and P values\0.05 were re-
garded as being statistically significant. Clinical factors such as re-
cipient age, gender mismatch (female donor/male recipient),
CMV status, stem cell source and treatment regimens were also in-
cluded in the analyses.
Multivariant analysis of the whole HSCT cohort demonstrated
that patients possessing the A allele were more susceptible to devel-
oping severe aGvHD (grades III-IV) (P5 0.028). Patients receiving
transplants from donors with the IL1312044 A allele were more at
risk of developing cGvHD (P 5 0.026). These associations re-
mained significant when the cohort was stratified for transplant
type (HLA-matched sibling andmatched unrelated donor) and con-
ditioning regimen (T replete vs deplete and reduced vs full intensity
conditioning). Significant associationswere also observed in a subset
of patients diagnosed with CML; HLA-matched sibling patients
possessing the IL13 12044 A allele were less likely to develop
cGvHD, whereas inMUD transplants donor possession of the A al-
lele was a risk for cGvHD. Depending on the subset analysis, clin-
ical factors, particularly peripheral blood stem cell transplants, were
significantly associated with GvHD.
To our knowledge this is the first investigation examining the role
of IL1312044 SNP in HSCT. The findings are extremely encour-
aging, indicating that IL1312044 SNP is associated with the devel-
opment of both aGvHD and cGvHD and consequently could
provide key pre-transplant information on GvHD prognosis.29
ADDITION OF ETANERCEPT TO METHYLPREDNISOLONE AS INITIAL
THERAPY FOR ACUTE GVHD RESULTS IN HIGH RESPONSE RATES AND
IMPROVED SURVIVAL
Levine, J.E., Paczesny, S., Mineishi, S., Braun, T., Choi, S.W.,
Hutchinson, R.J., Jones, D., Khaled, Y., Kitko, C.L., Bickley, D.,
Krijanovski, O., Reddy, P., Yanik, G., Ferrara, J.L.M. University of
Michigan, Ann Arbor, MI.
Standard therapy for GVHD, high dose steroids, results in com-
plete responses in only 35%of patients. Because tumor necrosis fac-
tor (TNF) is an important effector of GVHDwe treated 61 pts with
new onset GVHDwith methlyprednisolone 2 mg/kg/d plus etaner-
cept, a TNF inhibitor. All pts continued their prophylaxis agent,
usually tacrolimus, at therapeutic dosing.Etanercept was given subcutaneously 2 weekly for 8 wks at
a dose of 0.4 mg/kg/dose (max dose 25 mg). The outcomes in these
61 pts were compared to those of 99 contemporaneous pts with
GVHD whose initial therapy was steroids alone. Both groups of
pts were similar with respect to age, transplant conditioning inten-
sity, donor type, degree of HLA-match, and severity of GVHD at
onset. Pts who acheived CR by 4 wks did so without any second
line agents. Pts treated with etanercept plus steroids were signifi-
cantly more likely to achieve a complete response 4 wks later than
were pts treated with steroids alone [69% vs 33%, p\ 0.0001].
The benefit of etanercept persisted: at 12 wks after initiation of
GVHD treatment, 77% of etanercept plus steroids pts had achieved
CR compared to 50% of steroids alone pts (p5 0.0009). The supe-
riority of etanercept plus steroids over steroids alone was observed
in in all three target organs. Differences in steroid dosing did not
account for the difference in CR rate.
There was a trend for better survival at 6 mo following initiation
of GVHD treatment for the etanercept treated pts [p5 0.08] which
is explained by significantly superior survival in the unrelated donor
pts whoseGVHDwas treatedwith etanercept. Although related do-
nor pts who were treated with etanercept plus steroids were more
likely to be in CR at 4 wks [79% vs 39%, p 5 0.001], by 12 weeks
nearly equivalent proportions of pts in both groups achieved a CR
(etanercept plus steroids, 80%, steroids alone 70%) and 6 mo sur-
vival was similar. A greater proportion of unrelated donor pts
treated with etanercept were in CR at 4 wks [53% vs 26%, p 5
0.0005] but, unlike related donor pts, steroids alone pts who failed
to achieve a CR by 4 wks were likely to never achieve CR. This dif-
ference in overall CR rate translated into better survival six months
later [p 5 0.05].
Although not a randomized trial, these data strongly suggest that
etanercept plus steroids as initial therapy for acute GVHD results in
improved complete response rates compared to steroids alone and
may improve survival, especially for unrelated donor transplant pts.
Complete Response Rates at Four Weeks According to Treatment Group
Steroids Etanercept
alone plus steroids p valueOverall 33/99 (33%) 42/61 (69%) \0.0001
Skin 32/68 (47%) 30/37 (81%) 0.0008
Liver 3/15 (20%) 6/9 (67%) 0.03
GI 21/44 (48%) 29/37 (78%) 0.005
Presenting grade
Grade II 25/68 (37%) 31/40 (77%) 0.0001
Grade III/IV 8/31 (26%) 11/21 (52%) 0.0530
A FULLY-HUMAN CHIMERIC ANTIGEN RECEPTOR FOR REDIRECTING
SPECIFICITY OF T CELLS TO B-LINEAGE TUMORS
Manuri, P.R.1, Olivares, S.1, Dara, N.1, Dawson, M.J.1, Huls, H.1,
Lee, D.A.1, Shpall, E.J.2, Champlin, R.E.2, Cooper, L.J.N.1. 1Children’s
Cancer Hospital, U.T.M.D. Anderson Cancer Center, Houston, TX;
2U.T. MD Anderson Cancer Center, Hoouston, TX.
Adoptive therapy after allogeneic hematopoietic stem-cell trans-
plantation with ex vivo-expanded donor-derived tumor-specific T
cells to augment the graft-versus-leukemia (GVL) effect might be
used to reduce the incidence of leukemic relapse without exacerbat-
ing graft-versus-host disease. We previously showed that geneti-
cally modified peripheral- and umbilical cord blood-derived T
cells rendered specific for CD19, a molecule constitutively ex-
pressed on B-cell malignancies can augment GVL-effect. The re-
directed specificity was achieved by electro-transfer of a DNA
plasmid coding for the chimeric antigen receptor (CAR) that recog-
nizes CD19 via the scFv of a murine CD19-specific monoclonal an-
tibody (mAb) fused to T-cell activation endodomains. However,
